How has this study helped patients and researchers?
Information from this study may help doctors learn more about P. vivax malaria and its
treatment. The data from this study will be used to support the approval of
tafenoquine as a new medicine to prevent P. vivax malaria from returning after the
initial infection has been treated.
Are there plans for further studies?
Other studies of tafenoquine in patients with malaria are currently ongoing. The results
of these studies will also be available on the ClinicalTrials.gov website after the studies
end and the results are analysed.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries and other information.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events.
Organization Study Study
Website
Part Number
United States Part 2 www.clinicaltrials.gov NCT01376167
National Institutes
of Health (NIH)
GlaxoSmithKline Part 1 www.gsk- 112582
(GSK) clinicalstudyregister.com
For readers of this document in printed form, the websites that go with the internet
links above are
https://clinicaltrials.gov/ct2/show/NCT01376167?term=112582&rank=1
https://www.gsk-clinicalstudyregister.com/search/?study_ids=112582
Your doctor can help you understand more about this study and the results. You should
not make changes to your care based on the results of this or any single study. Keep
taking your current treatment unless instructed by your doctor.